Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : UTHR-a Promising Biotech in the works here? -- Ignore unavailable to you. Want to Upgrade?

To: debra vogt who wrote (13)	8/20/1999 4:54:00 AM
From: red_dog	Read Replies (1) \| Respond to of 66

kendall I have followed some of your post on Market Gems in the past, and figured that I owed you a couple of bucks for some of the picks that I made a few dollars on. <bg> So I dug up a few facts to answer Debra's question, I hope it will be of help. Positive results in phase II study of its lead compound, UT-15, in patients with mild to moderate hepatic impairment associated with Portopulmonary Hypertension. (a well-recognized complication of chronic liver disease) Without checking I would venture to say there are not a lot of people in need,(this in no way is to say that it isn't important) but would have to check further to get a specific number. Now pulmonary hypertension effects mostly young women and is the leading cause of lung transplants. Just found this information: Approximately 50,000 people are estimated to be diagnosed with life threatening pulmonary hypertension. Many of these are said to have developed the disease as a result of taking the diet drugs Redux and Phen-fen. To some up with what I have found so far. The primary therapies for these patients today are lung transplants or lifelong, 24 hour-a-day intravenous of a drug called prostacyclin. UT-15 therapy is intended to be a safer subcutaneous formulation of prostacyclin. I know that doesn't answer all of your question but it's been a while since I had to do an essay on unfamiliar subject. <bg> Flash! Found some more information: I have just found that UT-15 had positive results in phase II in patients with moderate to severe peripheral vascular disease (PVD). A disease that affects more than 2 million people in North America. I believe that you will find that number to be very much larger in the far east. This is only my opinion! Rg

To: debra vogt who wrote (13)	8/20/1999 5:12:00 PM
From: kendall harmon	Respond to of 66

Debra this is an excellent question. The first thing I would encourage you to do is to spend some time on the UTHR website: unither.com They have information there about exactly this on the front page. They even have figures in terms of incidence per hour. It is a potentially HUGE market, epitomized by their figure that on this disease (pulmonary hypertension) in America and Europe over 7 billion dollars a year is spent overall. Obviously the world figures would be even higher, were a place such as China to be taken into account.

To: debra vogt who wrote (13)	8/25/1999 6:44:00 AM
From: kendall harmon	Read Replies (1) \| Respond to of 66

UTHR--Another aspect of this story is that 685,000 shares have been sold short. I was surprised by the amount but it is available via both Yahoo and www.viwes.com. This amounts to more than 15% of the current float, and, with average daily volume of 64,000 shares, gives a short ratio of over 10. A further factor which could lead to a big up move in the stock if the news next week and beyond is good.

To: debra vogt who wrote (13)	8/28/1999 2:49:00 PM
From: kendall harmon	Respond to of 66

UTHR could still go higher next week, depending on the outcome of the paper to be delivered in Barcelona this coming Tuesday morning European time. The company is going to have an accompanying press release Tuesday evening U.S. time (confirmed to me through communications with IR). The market for their lead drug, UT-15, is very large, consider just one fact: The prevalence of x-ray measured pulmonary arteries with abnormally large diameters -- an indication of pulmonary hypertension -- is 13% of men over age 34. This means there may be tens of millions of people worldwide with pulmonary hypertension. The prevalence of people with diagnosed Primary Pulmonary Hypertension (PPH) is about ten persons per million. The number of diagnosed case of secondary pulmonary hypertension is approximately 50,000 persons in the U.S.and Europe.